Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kopp HG et al. - Novel compounds such as bevacizumab, multi-tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, imatinib, and the thrombospondin agonist ABT 510 represent attractive partners for the above-mentioned cytostatic agents, or may even be effective single agents in the clinically advanced setting.


Today in Clinical Pharmacology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

A practical approach to using methotrexate
Dermatology in Practice, 10/09/09

Ustekinumab for the treatment of plaque psoriasis
Expert Review of Dermatology, 10/13/09

Today in Dermatologic Oncology...keeping you current

A practical approach to using methotrexate
Dermatology in Practice, 10/09/09

Melanoma Thickness Trends in the United States, 1988-2006
Journal of Investigative Dermatology, 10/19/09

Childhood melanoma
Clinics in Dermatology, 11/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address